Table 3.
Results of the univariate and multivariate analyses of OS in the total cohort and in the PET-positive and PET-negative subgroups.
| Criteria | All populations | PET-positive subgroup | PET-negative subgroup | |
|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Multivariate analysis | Multivariate analysis | |
|
P-value HR (95% CI) |
P-value HR (95% CI) |
P-value HR (95% CI) |
P-value HR (95% CI) |
|
| Recurrence PSA (≥1.2 vs. <1.2) |
0.009* 2.86 (1.30-6.27) |
0.027* 2.53 (1.11-5.75) |
0.055 2.57 (0.98-6.76) |
|
| Post-surgery PSA (≥0.2 vs. <0.2) |
0.044* 1.95 (1.02-3.75) |
0.051 3.42 (0.99-11.79) |
||
| No. of positive sites at PET/TC 1-3 >3 |
0.037* 0.47 (0.23-0.96) 0.031* 3.82 (1.13-12.91) |
0.001* 9.17 (2.40-35.04) |
||
| Chemotherapy at recurrence (yes vs. no) |
0.009* 2.86 (1.30-6.27) |
0.001* 3.95 (1.81-8.64) |
0.043* 4.24 (1.05-17.18) |
0.006 3.81 (1.47-9.90) |
| Hormone therapy at recurrence (yes vs. no) |
0.081 1.87 (0.93-3.78) |
|||
*Significant results.